Hatteras Venture Partners announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I) with over $200 million in capital commitments from limited partners. This milestone comes as Hatteras celebrates investing in its 100th portfolio company and marks 25 years of building transformational human medicine companies. “Last week, our portfolio company HistoSonics announced its strategic acquisition in a landmark transaction.
Across 100 portfolio companies and 25 years, we’ve had exhilarating wins and some heartbreaking disappointments,” said Clay Thorp, General Partner of Hatteras Venture Partners. “The relationships we’ve developed with scholarly innovators, committed entrepreneurs, and resilient co-investors have been the most gratifying. We look forward to continuing our investment in transformative life sciences companies disrupting healthcare and accelerating innovation.”
Established in 2000 with Hatteras Venture Partners I, LP, a seed-stage venture fund with $2.93 million in capital, Hatteras now manages over $900 million in capital focused on seed- and early-stage companies in biotechnology, medtech, and healthtech.
Some highlights from HVP I to HVP VII include:
HistoSonics, Inc. developed histotripsy for tissue destruction using ultrasound. The Edison Histotripsy System was FDA approved in October 2023.
HistoSonics was acquired for $2.25 billion. Kymera Therapeutics, Inc. is a leader in targeted protein degradation.
Hatteras celebrates 25 years of investments
The company closed a successful IPO in 2020 and currently has a market capitalization greater than $3 billion. G1 Therapeutics, Inc.
developed trilaciclib for bone marrow protection during chemotherapy. Hatteras led the seed round and the company went public with a $105 million IPO in 2017. G1 was acquired by Pharmacosmos in 2024.
In addition to expanding its capital base, Hatteras has promoted two key members of its team:
Ben Scruggs, Ph.D. was promoted from Principal to Partner, focusing on biopharmaceuticals and tools investments. Ben also leads Altis Biosystems as CEO. Lauren Flickinger was promoted from Principal to Partner.
Lauren, who joined Hatteras in 2021 from Morgan Stanley, manages the Pisgah Fund in Asheville, N.C., and leads Hatteras’s health technology portfolio. “Ben and Lauren possess the values, instincts, and tenacity we need to lead Hatteras into the future,” said John Crumpler, Co-Founder and General Partner of Hatteras Venture Partners. “Their leadership in HVP VII is tremendous, and I look forward to continuing our work together.”
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, N.C. specializing in seed- and early-stage investments in biopharmaceuticals, medical devices, and health technology companies.
The firm manages over $900 million through seven venture capital funds and is known for its successful track record in company formation and early-stage investing.
